Passage Bio Expands Leadership with New Board Appointment
![Passage Bio Expands Leadership with New Board Appointment](https://investorshangout.com/images/blog/ihnews-Passage%20Bio%20Expands%20Leadership%20with%20New%20Board%20Appointment.jpg)
Passage Bio Welcomes Tom Kassberg to Board of Directors
Passage Bio, Inc. (Nasdaq: PASG), a pioneering company focused on developing genetic medicines aimed at addressing neurodegenerative diseases, is excited to announce the appointment of Tom Kassberg to its Board of Directors. Alongside his new position, Kassberg will also be a member of the Audit Committee, bringing significant expertise to the table.
Experience and Leadership Qualities of Tom Kassberg
Mr. Kassberg currently serves as the Chief Business Officer and Executive Vice President at Ultragenyx, a company dedicated to creating innovative therapies for rare genetic conditions. His extensive experience in business development and alliance management has been vital to advancing treatments, including several gene therapies in later-stage development. This background makes him an invaluable asset to Passage Bio during such a pivotal time for the organization.
Quotes from Leadership
Will Chou, M.D., president and CEO of Passage Bio, expressed the company's enthusiasm about this new appointment: "We are pleased to welcome Tom Kassberg to the Passage Bio Board of Directors, where he will play an influential role in driving our mission forward during this critical time for the organization. His deep understanding of strategic planning and corporate development makes him exceptionally well-equipped to guide Passage Bio as we pursue PBFT02 across several neurodegenerative indications. We're thrilled to have him join our team."
Kassberg’s Background in Biotechnology
Before joining Ultragenyx, Kassberg held an executive role at Proteolix, Inc. as the Executive Vice President of Corporate Development, where he spearheaded strategic initiatives and business development activities. Earlier in his career, he was the Senior Vice President of Corporate Development and Commercial Operations at InterMune, Inc. He co-founded Plexxikon and played a crucial role there, alongside significant contributions at SUGEN, where he was instrumental during its acquisition by Pharmacia. Mr. Kassberg’s journey began at Bristol Myers Squibb, where he honed his skills in strategic planning, sales, and financial analysis.
Vision for the Future
Mr. Kassberg conveyed his eagerness to be part of the Board, stating, "I am excited to join the Passage Bio Board of Directors and contribute to the continued growth of the company. The remarkable progress of the PBFT02 program and opportunity to expand into additional indications highlight Passage Bio’s dedication to making a critical impact in the field of neurodegenerative diseases. I look forward to collaborating with this exceptional team to drive forward our promising treatments and make a meaningful impact on the lives of patients and their families."
About Passage Bio
Passage Bio (Nasdaq: PASG) is at the forefront of genetic medicine, focusing on innovative therapies tailored for patients grappling with neurodegenerative diseases. The company’s mission is not just to develop treatments but to fundamentally enhance the quality of life for these patients. Its leading candidate, PBFT02, aims to treat conditions like frontotemporal dementia through innovative methodologies that restore lysosomal function and slow disease progression.
Passage Bio is dedicated to advancing its groundbreaking work while remaining steadfast in its commitment to patients and their families facing the devastating impact of neurodegenerative disorders. For more details about Passage Bio’s groundbreaking initiatives, you can visit www.passagebio.com.
Contact Information
For further inquiries, please reach out to:
Investors:
Stuart Henderson
Passage Bio
267.866.0114
shenderson@passagebio.com
Media:
Mike Beyer
Sam Brown Inc. Healthcare Communications
312.961.2502
MikeBeyer@sambrown.com
Frequently Asked Questions
What role is Tom Kassberg taking at Passage Bio?
Tom Kassberg has been appointed to the Board of Directors and the Audit Committee at Passage Bio.
What is the primary focus of Passage Bio?
Passage Bio specializes in developing genetic medicines aimed at combating neurodegenerative diseases.
What is PBFT02?
PBFT02 is Passage Bio's leading product candidate designed to treat frontotemporal dementia by targeting underlying disease mechanisms.
What experience does Kassberg bring to Passage Bio?
Kassberg brings extensive experience in business development and corporate strategy from his previous roles at Ultragenyx and Proteolix, among others.
How can I find more information about Passage Bio?
More information about Passage Bio’s mission and projects can be found on their official website at www.passagebio.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Adia Nutrition Welcomes Dr. Richard Edwards as New Medical Director
- AffiniPay’s New CMO Nate Skinner Aims for Growth and Innovation
- SiLC Technologies Enhances AI Vision with Honda's Investment
- Enhancing Client Engagement at FNBO with Q2 Treasury Solutions
- Calavo Growers Surprises Investors with Strong Q3 Earnings
- Exciting Partnership: Getaway Space Teams Up with Urth Caffé
- SSIP Partners with Integrity for Enhanced Senior Insurance Solutions
- AG Mednet Strengthens Leadership with New Executive Hires
- VitalHub Corp Shines in Latest TSX30 Rankings with Growth
- Marlowe Naples Features Luxury Living with Modern Amenities
Recent Articles
- Exciting Developments at VCI Global in AI and Shareholder Value
- Kreshmore Group Facilitates Strategic Acquisition of IFE
- Veracode Platform Shows Significant ROI and Enhances Security
- Wynn Resorts Plans $800 Million Offering to Strengthen Capital
- Amesite's Revolutionary AI Solutions Transform Education and Healthcare
- Navigating Market Fluctuations Amid Election Uncertainty
- BOE's Innovative Conference Unveils Cutting-Edge Technologies
- Netskope Enhances Security and Networking with AI Innovations
- Discure Technologies Secures $16 Million for Medical Innovation
- Doug Nicholson Joins Pathlight Capital as New Managing Director
- QurAlis Advances Groundbreaking ALS Therapy QRL-101 with New Trials
- Rami Daoud Joins Affinia Therapeutics as New CFO
- Gary Kelly Announces Retirement from Southwest Airlines Leadership
- Robert Kiyosaki's Predictions for Financial Success by 2034
- Understanding Market Movements Amid Upcoming Presidential Debate
- The Best Dividend Growth Stocks for Steady Retirement Income
- Altimmune's Phase 2 Study Shows Promising Body Composition Results
- Nayax and A2Z Cust2Mate Forge Payment Revolution in Retail
- Opthea Showcases Innovations at the EURETINA Congress 2024
- Bird Construction Achieves Great Milestones with TSX30 Recognition
- Elevai Labs Explores Innovative Melasma Treatments with Exosomes
- Leading Changes at Saputo: New Executive Appointments Announced
- Exciting Developments at Jasper Therapeutics for Asthma Trials
- TC Energy Corporation Updates on Equity Purchase Agreement
- Mattr Corp Achieves Recognition on TSX30 for 2024
- Bombardier Secures Spot on TSX30 for Exceptional Stock Growth
- Alliance Trust PLC Updates Net Asset Value for Investors
- Exciting Opportunities: 3 Promising Health Care Stocks
- Insider Stock Moves: System1 and Other Low-Cost Stocks to Watch
- Bird Construction Achieves TSX30 Recognition and Index Inclusion
- Fidelity's Money Gains: Empowering Young Investors with Knowledge
- Bombardier Celebrates Strong Market Presence with TSX30 Honor
- Scioto Properties Expands Reach with $80 Million Acquisition
- Denodo Launches University Challenge to Harness Data for Change
- Discover Your Dream Home with My Place Group Today!
- Promising Copper Intersections Highlight La Romana Project Growth
- Comvest Credit Partners Launches $500 Million CLO for Investors
- Trinity Street Capital Secures $64MM Loan for Unique Project
- Cornerstone Enhances Operations with Funnel's AI-Powered CRM
- Petro-Victory Energy Partners with Eneva to Boost Gas Resources
- Exploring Nordea Group's Innovation Through Digital Transformation
- Ashcroft Capital Expands Portfolio with Halston Waterleigh
- GoGold Resources Progress on Los Ricos Feasibility Study
- Jones Soda Unveils New S'mores Flavor Inspired by Campfires
- Valour Achieves Record Growth in Assets Under Management and Inflows
- LightInTheBox Announces Annual Meeting for Shareholders
- Conagra Brands Foundation Fosters Community Growth with Grants
- Discover Generac's Latest Innovations in Home Energy Storage
- Embr Labs Excels as a Quarterfinalist in Digital Health Awards
- Carisma and Moderna Team Up for New Autoimmune Therapies